The presence of ANK1, HSPA4, HSP90AB1, DNMT1, RPS27, FTL, NCL and A2M in the metastatic CRC patients is highly evocative yet we do not know if they are acting in synergy with each other and if so which one of them would be the key protein beside the EGFR in panitumumab efficacy. This evidence concerns the gene A2M and colorectal carcinoma.